Effects of taurine on blood sugar and inflammation in people with Type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the impact of taurine, a semi-essential amino acid, on glycemic control, lipid levels, and inflammation in individuals diagnosed with Type 2 diabetes mellitus (DM2). A total of 94 participants will be randomly assigned to receive either taurine or a placebo for 12 weeks, with various blood and urine tests conducted to assess changes in key health markers. The study aims to determine if taurine can improve health outcomes for those who struggle to meet glycemic targets with conventional treatments. Participants will also be monitored for adverse effects throughout the trial.

Why it matters

Who can join: the full rules

Inclusion criteria

* Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;
* Age over 30 years;
* BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;
* HbA1c between 7.5% and 10.5%.

Exclusion criteria

* Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;
* Pregnancy or lactation;
* Chronic renal failure with glomerular filtration rate calculated by MDRD \< 30 mL/h;
* Myocardial infarction in the last than 6 months
* Current neoplasia;
* Chronic use of glucocorticoids;
* Bariatric surgery.

Where it's running

• Hospital de Clínicas
  Porto Alegre, Rio Grande do Sul, Brazil Recruiting

Study contacts

• Principal investigator: Beatriz D Schaan, PhD — Hospital de Clinicas de Porto Alegre
• Study coordinator: Beatriz D Schaan, PhD
• Email: bschaan@hcpa.edu.br
• Phone: 55 51 3359-8000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proliverenol for liver fat and insulin resistance in type 2 diabetes

  This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.

  Recruiting Phase 2 Universitas Sriwijaya · Palembang, South Sumatera · NCT07928661

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

  This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.

  Recruiting Bionime Corporation · Ulm, Baden-Wurttemberg · NCT07889388

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.